Financial HighlightsFor the three months Ended 31 March 2026(HK$ million)20262025ChangeRevenue 1,115.61,071.9+ 4.1%Gross Profit402.1376.1+ 6.9%Gross Profit margin36.0%35.1%+ 0.9ppProfit attributable to owners of the Company122.4110.0+ 11.3%Net profit margin11.0%10.3%+ 0.7ppAdjusted EBITDA 209.0201.5+ 3.7%Earnings per share (HK cents)11.7310.54+ 11.3%HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its unaudited first quarter financial results for the three months ended 31 March 2026 (the “Reporting Period”).The Group reported revenue of HK$1,115.6 million for the Reporting Period, representing an increase of 4.1% from HK$1,071.9 million of the corresponding period of 2025. Gross profit increased by 6.9% year-on-year to HK$402.1 million, due to the continued implementation of cost efficiency initiatives. Gross profit margin increased by 0.9 percentage points to 36.0% from 35.1% of the corresponding period of 2025 mainly attributable to the increased sales volume of the core brands to absorb cost pressure. Profit attributable to owners of the Company notably increased by 11.3% year-on-year to HK$122.4 million, while Adjusted EBITDA grew by 3.7% year-on-year to HK$209.0 million.Revenue from Hong Kong and other regions operations increased moderately by 3.1% due to the stable performance of the noodles business, particularly the Group’s core brands of Cup Noodles and Demae Iccho. As for the Chinese Mainland operations, revenue increased by 4.6% due to the sales expansion in the inland areas and the appreciation of Renminbi to Hong Kong Dollars.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Building on the solid momentum established in 2025, the Group delivered another quarter of resilient growth, with steady performance across our key markets. Revenue and profitability improved year-on-year, supported by stable sales volumes. Our core noodles business continued to perform well across regions, while our premiumisation and diversification strategies gained further traction in the Chinese Mainland. With a balanced regional footprint and enhanced operational execution, the Group remains well positioned to deliver sustainable growth and long-term value for shareholders.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ORLANDO, FL, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers, ‘almost right’ just isn’t good enough,” said Christian Klein, CEO of SAP SE. “By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

丹麦比隆, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 在乐高基金会年度会议上，董事会选举阿格妮特·柯克·克里斯蒂安森担任董事会主席。作为乐高集团所有者柯克·克里斯蒂安森家族的第四代成员，她成为该基金会自1986年成立以来仅有的第五位主席。阿格妮特·柯克·克里斯蒂安森自2023年起担任乐高基金会副主席，此次接替其兄长托马斯·柯克·克里斯蒂安森出任主席，后者卸任后将担任副主席。除在乐高基金会的职务外，阿格妮特·柯克·克里斯蒂安森还担任家族控股及投资公司KIRKBI A/S的副主席，该公司持有乐高集团75%的股份。作为新任主席，阿格妮特·柯克·克里斯蒂安森强调了乐高基金会在为全球儿童创造更美好未来方面所发挥的作用：· “能够接任乐高基金会主席一职，并继续我们为儿童开展的重要工作，我深感荣幸。自40多年前成立以来，该基金会在我们家族中一直占据着非常特殊的地位。为儿童创造积极影响的深切责任感贯穿于我们家族的始终，我坚信每个孩子都应有机会茁壮成长。我为能为这一使命贡献力量并助力其传承而感到自豪。此次主席交接发生在阿格妮特接任非营利基金会“奥勒·柯克基金会”（Ole Kirk's Fond）主席一职的次年。随着这一交接，家族第四代成员正进一步拓展其参与范围，并致力于践行积极所有权。卸任主席托马斯·柯克·克里斯蒂安森表示：· 过去10年担任乐高基金会主席是我莫大的荣幸，如今能将这一职责移交给阿格妮特，我感到非常高兴。她对乐高基金会的使命怀有深切的热忱，我相信她将竭尽全力，为“保障所有儿童的童年”这一事业贡献力量。“在担任副主席期间，她为制定基金会当前的战略发挥了关键作用。随着她接任主席一职，我们将进一步扩大家族在整个乐高生态系统中的积极所有权和参与度。”托马斯·柯克·克里斯蒂安森自2016年起担任乐高基金会主席，在此期间，基金会通过全球合作伙伴组织承诺拨款超过150亿丹麦克朗（20亿欧元），致力于改善儿童福祉。· “40年来，乐高基金会始终致力于回馈社会，为儿童构建更美好的世界。我们深知家庭和社区对我们的信任，这份责任我们绝不轻视。即使在最艰难的环境中，基金会也能帮助孩子们展露笑颜，激励不同能力水平的学习者，并改变他们的人生轨迹。我们将以最敏锐的洞察力和最负责任的态度践行这一使命，”阿格妮特·柯克·克里斯蒂安森表示。作为乐高集团的股东之一，乐高基金会不仅致力于保障集团的持续发展与成功，更通过资助并紧密合作于Brac、IRC、联合国儿童基金会、救助儿童会、挪威难民理事会等组织，践行其慈善使命，支持教育、研究及儿童发展领域的各项倡议。乐高基金会董事会其他变动除阿格妮特与托马斯·柯克·克里斯蒂安森分别担任主席和副主席外，乐高基金会董事会还在5月的会议上选举英格丽德·斯坦格为董事会成员，她拥有丰富的慈善、教育及非营利组织领导经验。此外，乐高集团前首席执行官约尔根·维格·克努德斯托普（Jørgen Vig Knudstorp）以及红十字会与红新月会国际联合会前秘书长埃尔·哈吉·阿马杜·盖耶·西（El Hadji Amadou Gueye Sy，简称As），在为乐高基金会服务16年和4年后，分别离开了董事会。托马斯·柯克·克里斯蒂安森（Thomas Kirk Kristiansen）对两位离任的董事会成员长期以来对基金会的奉献表示感谢：· 我们非常期待欢迎英格丽德的加入，她将为董事会带来高度互补的专业知识。同时，我感谢阿斯（As）为我们提供了宝贵的见解和经验，帮助塑造了我们的工作。· 我还要向约尔根表达最诚挚的谢意，感谢他对基金会的坚定奉献。在任职期间，约尔根在制定我们的愿景和战略方面发挥了关键作用，同时始终没有忘记我们所服务的儿童。此外，自2021年起担任董事会成员的玛露·阿蒙德，接任了基金会第二副主席的职务。个人简介：阿格内特·柯克·克里斯蒂安森乐高基金会2026年 - 董事会主席2023年至2026年 - 董事会第二副主席2008年起 - 董事会成员KIRKBI A/S2024年 - 董事会副主席ADHD+中心，丹麦奥胡斯创始人奥勒·柯克基金会2025年 - 董事会主席学历2010年，奥胡斯大学心理学专业其他现任及曾任职务：· KIRK83 Holding ApS 执行经理· Ruca 顾问委员会成员· 乐高所有者家族第四代代表· 在家族企业、长期管理及董事会工作中拥有丰富经验乐高基金会董事会阿格内特·柯克·克里斯蒂安森 - 主席托马斯·柯克·克里斯蒂安森 - 第一副主席马洛·阿蒙德 - 第二副主席希拉里·彭宁顿 - 董事会成员英格丽德·斯坦格 - 董事会成员乐高基金会董事会主席1986 - 1993：戈特弗雷德·柯克·克里斯蒂安森（乐高第二代所有者）1993 - 2000：本特·斯科夫2000 - 2016：凯尔德·柯克·克里斯蒂安森（乐高第三代所有者）2016 - 2026：托马斯·柯克·克里斯蒂安森（乐高第四代所有者）2026 - 阿格妮特·柯克·克里斯蒂安森（乐高第四代所有者）关于乐高基金会：乐高基金会是一家丹麦企业基金会，受托持有乐高集团25%的股权。该基金会与全球合作伙伴携手，致力于满足儿童需求，捍卫童年的尊严。通过慈善捐赠和影响力投资，该基金会致力于为世界各地的每个孩子创造茁壮成长的条件和空间。有关乐高基金会的更多信息，请访问： https://www.legofoundation.com/ 联系方式：马德斯·赫维特·格兰德mads.hvitved.grand@legofoundation.com 来源：乐高基金会 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务撮要截至2026年3月31日止三个月(百万港元)20262025变动收入 1,115.61,071.9+ 4.1%毛利402.1376.1+ 6.9%毛利率36.0%35.1%+ 0.9个百分点本公司拥有人应占溢利122.4110.0+ 11.3%纯利率11.0%10.3%+ 0.7个百分点经调整EBITDA209.0201.5+ 3.7%每股盈利（港仙）11.7310.54+ 11.3%香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，连同其附属公司统称「集团」；股份代号：1475）今天公布截至2026年3月31日止三个月（「报告期」）之未经审核第一季度财务业绩。报告期内，集团录得收入1,115.6百万港元，较2025年同期的1,071.9百万港元增加4.1%。毛利按年上升6.9%至402.1百万港元，主要由于持续实施成本效益措施所致。毛利率由2025年同期的35.1%增加0.9个百分点至36.0%，主要由于核心品牌销量增加，消化了成本压力。本公司拥有人应占溢利录得122.4百万港元，按年显著上升11.3%；经调整EBITDA则按年增长3.7%至209.0百万港元。来自香港及其他地区业务的收入增加3.1%，此乃由于面类业务表现稳健，特别是集团核心品牌合味道及出前一丁。内地业务收入增加4.6%，主要受惠于内陆地区的销售扩大及人民币兑港元升值所致。日清食品执行董事、董事长兼首席执行官安藤清隆先生表示：「延续2025年建立的良好增长势头，集团于本季度持续录得稳健的业务表现，主要市场的营运表现保持平稳。收入及盈利按年有所提升，主要受稳定的销售量所支持。核心方便面业务于各地区持续表现理想，而高端化及多元化策略亦于中国内地进一步取得成效。凭借均衡的地域布局及持续提升的营运执行力，集团有信心为股东创造可持续的长远价值。」有关日清食品有限公司日清食品有限公司（「日清食品」，连同其附属公司统称「集团」；股份代号：1475）为一间在中国内地及香港知名的食品公司，主要专营优质方便面市场，旗下众多品牌不仅知名度高，且广受顾客喜爱。集团于1984年正式于香港设立营业据点并为香港最大的方便面公司。集团主要生产及销售两个核心企业品牌「日清」及「公仔」，以及多元化的家庭食品品牌组合，出品具标志性和优质的方便面、优质冷冻食品（包括冷冻点心及冷冻面条）并销售和分销其他食品及饮料产品（包括蒸煮袋装产品、零食、矿泉水、酱料及蔬菜产品）。集团五个旗舰品牌「合味道」、「出前一丁」、「公仔面」、「公仔点心」及「福」在香港亦是其各自食品类别中最受欢迎的选择。中国内地市场方面，集团以创新技术推出「ECO杯」概念，销售活动主要集中在中国内地的一线及二线城市。此外，日清食品在其他地区开展业务，包括越南、台湾、韩国及澳洲市场。日清食品被纳入5项恒生指数，包括恒生综合指数、恒生综合小型股指数、恒生综合行业指数-必需性消费、恒生港股通消费行业指数和恒生港股通食品饮料消费指数。日清食品现可通过沪港通及深港通下港股通进行交易。详情请浏览www.nissingroup.com.hk。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CALGARY, AB AND VANCOUVER, BC / ACN Newswire via SeaPRwire.com / May 12, 2026 / CANEX Metals Inc. ("CANEX") (TSXV:CANX) and Gold Basin Resources Corporation ("Gold Basin") (TSXV:GXX) are pleased to announce that they have entered into a definitive agreement (the "Arrangement Agreement") to combine their respective businesses by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). The combined company will be managed by the CANEX executive team.Under the terms of the Arrangement, shareholders of Gold Basin ("Gold Basin Shareholders") will receive 0.592 shares of CANEX ("CANEX Shares") per share of Gold Basin ("Shares") held, the same consideration received by Gold Basin Shareholders who tendered to the CANEX offer to acquire Shares which expired on February 10, 2026. This represents a premium of 242.0% to the last trading price of the Shares prior to the Cease Trade Order, based on the closing price of the CANEX Shares as of May 8, 2026.Dr. Shane Ebert, President and CEO of CANEX stated: "Today's announcement of an agreement to combine the two companies will allow us to consolidate and advance a promising gold district in Arizona. CANEX will be pleased to welcome Gold Basin Shareholders as new shareholders of CANEX."Jordan Ross, independent director and Chair of the Gold Basin Special Committee, commented: "The Arrangement Agreement represents a strategic milestone for our shareholders. By partnering with CANEX, we are unlocking the full potential of our Arizona project while providing a stable, clear-cut path forward that resolves previous liquidity and regulatory challenges. Following a rigorous review with our professional advisors, we are confident this agreement offers the most robust and value-driven future for our investors."Benefits to Gold Basin ShareholdersSignificant Upfront Premium to Shareholders. The consideration offered under the Arrangement represents a 242.0% premium to the last trading price of the Shares prior to the Cease Trade Order, based on the closing price of the CANEX Shares as of May 8, 2026.Consolidation of Gold Districts and Near-Term Exploration and Expansion. The Arrangement will consolidate an advanced oxide gold exploration camp in Mohave County, Arizona hosting multiple zones of gold mineralization with strong drill results across an eight kilometre by eight kilometre area, opening up potential near-term exploration on favourable targets.Diversification. Completing the Arrangement will provide Gold Basin Shareholders not only with exposure to a consolidated gold district in Mohave County, Arizona, but also to CANEX's Louise Project in British Columbia. On July 31, 2025, CANEX announced results from an induced polarization geophysical survey which identified a new and previously unknown chargeability target two kilometres west of the historic Louise deposit and a large steeply dipping zone of high chargeability below and to the north of the historic Louise deposit.Focused, Professional and Cost-Effective Management Team. The Arrangement places the consolidated district under CANEX's highly focused, professional and cost-effective management team, which will provide strong operational and governance oversight.Experienced Board of Directors. Following the Arrangement, the Resulting Issuer's board of directors will be led by experienced industry professionals, comprised of members of the current board of directors of CANEX.Liquidity. The Arrangement will provide Gold Basin Shareholders with a more liquid investment. On May 6, 2025, the British Columbia Securities Commission imposed a Cease Trade Order against the Gold Basin Shares. The next day, the Canadian Investment Regulatory Organization imposed a halt in trading of the Gold Basin Shares on the TSXV. There is no expectation that the Cease Trade Order will be rescinded if the Arrangement were not to proceed and Gold Basin were to continue with the status quo.Enhanced Financial Capacity. CANEX has demonstrated an ability to raise capital and has strong support from a number of high profile industry professionals. With an enhanced capital markets profile, the Resulting Issuer is expected have even better access to lower-cost capital and an increased capability to advance its exploration properties.Going Concern. In the absence of the Arrangement, there is considerable risk that Gold Basin will not have the ability to continue as a going concern and realize its assets and discharge its liabilities in the normal course of business. Currently, Gold Basin has asserted liabilities of over $2 million, no cash or marketable securities and no revenue. Gold Basin's ability to raise equity financing is restricted by the Cease Trade Order.Details of the ArrangementCANEX and Gold Basin entered into a definitive Arrangement Agreement on May 11, 2026, pursuant to which CANEX will acquire all of the issued and outstanding common shares of Gold Basin ("Gold Basin Shares") by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia).Holders of Gold Basin Shares ("Gold Basin Shareholders") will receive 0.592 common shares in the capital of CANEX (the "CANEX Shares", and such ratio being the "Exchange Ratio") in exchange for each Gold Basin Share held immediately prior to the effective time of the Arrangement. Upon completion of the Arrangement, existing holders of CANEX Shares and former Gold Basin Shareholders will own approximately 67.7% and 32.3% of the total issued and outstanding CANEX Shares, respectively, on a fully diluted basis.CANEX expects to issue an aggregate of approximately 38,505,033 CANEX Shares to Gold Basin Shareholders, based on the number of Gold Basin Shares outstanding as at the date of this announcement.The Arrangement is expected to close in June 2026, subject to the receipt of all required court, shareholder, regulatory, and stock exchange approvals. Following completion of the Arrangement, the CANEX Shares will remain listed on the TSXV and the Gold Basin Shares will be delisted from the TSXV.Term LoanConcurrently with the entering into of the Arrangement Agreement, CANEX and Gold Basin have agreed to enter into a senior secured term loan (the "Term Loan") as soon as practicable pursuant to which CANEX will lend up to $900,000 to Gold Basin at an interest rate per annum equal to the Royal Bank of Canada Prime Rate plus 5.0%. The maturity of the Term Loan shall be six months and the Term Loan shall be secured by a first ranking general security agreement over all of Gold Basin's present and after-acquired assets, a first ranking mortgage charge over Gold Basin's split mineral rights and first ranking security agreements encumbering all of Gold Basin's other mineral tenure. The proceeds from the Term Loan will be used by Gold Basin for aged payables, day to day working capital and general corporate expenditures, direct advances paid by CANEX to third party suppliers, service providers and creditors of Gold Basin, and expenses in connection with the Arrangement. The Term Loan is not contingent on the completion of the Arrangement.The Term Loan is subject to the approval of the TSXV. No fees are payable in connection with the Term Loan.Arrangement Conditions and TimingThe Arrangement will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) and will require the approval of: (i) at least 66⅔% of votes cast by Gold Basin Shareholders, and (ii) a simple majority of the votes cast by disinterested Gold Basin Shareholders, excluding for this purpose the votes held by any person specified under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. The Gold Basin Shares held by CANEX will not be excluded from either vote. CANEX currently holds 70,088,199 Gold Basin Shares, representing 51.86% of the issued and outstanding Gold Basin Shares.The Arrangement Agreement includes customary representations and warranties for a transaction of this nature as well as customary interim period covenants regarding the operation of CANEX's and Gold Basin's businesses. The Arrangement Agreement also includes customary deal protections in favour of each of CANEX and Gold Basin. With respect to CANEX, these protections include non-solicitation covenants, and a right to match any superior proposals. With respect to Gold Basin, these protections include a fiduciary-out provision. The Arrangement Agreement includes a termination fee of $211,777 payable by Gold Basin in the event the Arrangement Agreement is terminated in certain circumstances.In addition to securityholder and court approvals, the Arrangement is subject to applicable regulatory approvals, stock exchange approvals and the satisfaction of certain other closing conditions customary in transactions of this nature.None of the securities to be issued pursuant to the Arrangement have been or will be registered under the U.S. Securities Act, or any state securities laws, and any securities issuable in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.Further details of the Arrangement will be included in a management information circular to be prepared by Gold Basin (the "Gold Basin Circular") that will be delivered to Gold Basin Shareholders in advance of a special meeting of Gold Basin Shareholders (the "Gold Basin Meeting") which is scheduled to be held on June 4, 2026. A copy of the Arrangement Agreement will be made available on CANEX's and Gold Basin's respective SEDAR+ profiles at www.sedarplus.com. The Gold Basin Circular will also be made available on Gold Basin's SEDAR+ profile in advance of the Gold Basin Meeting.Board of Directors' and Special Committee RecommendationBased on the recommendation of a special committee comprised of an independent director of Gold Basin (the "Special Committee") and after consultation with independent external financial and legal advisors, the board of directors of Gold Basin (the "Gold Basin Board") unanimously approved the Arrangement and has determined the Arrangement is in the best interests of Gold Basin, and that the consideration to be received by Gold Basin Shareholders is fair, from a financial point of view, to Gold Basin Shareholders (other than CANEX). The Gold Basin Board unanimously recommends that Gold Basin Shareholders vote in favour of the Arrangement at the Gold Basin Meeting.Stifel Nicolaus Canada Inc. has provided a fairness opinions to the Gold Basin Board and Special Committee in connection with the Arrangement.Voting Support AgreementsEach of Gold Basin's directors and officers support the Arrangement and all who own Shares have entered into customary voting support agreements agreeing to vote their Gold Basin Shares, respectively, in favor of the Arrangement. The voting support agreement may be terminated in certain circumstances, including, without limitation, upon termination of the Arrangement Agreement.About CANEX MetalsCANEX Metals (TSX.V:CANX) is a Canadian junior exploration company and the controlling shareholder of Gold Basin Resources, owning 51.86% of Gold Basin. CANEX is advancing its 100% owned Gold Range Project in Mohave County, Arizona. With several near surface bulk tonnage gold discoveries made to date across a 4 km gold mineralized trend, the Gold Range Project is a compelling early-stage opportunity for investors. Gold Basin Resources holds the adjacent Gold Basin Project which hosts large, mineralized trends containing near surface oxide gold mineralization and has seen over 800 historic and current drill holes into mineralized deposits up to 1.7 kilometres in length.CANEX is also advancing the Louise Copper-Gold Porphyry Project in British Columbia. Louise contains a large historic copper-gold resource that has seen very little deep or lateral exploration, offering investors copper and gold discovery potential. CANEX is led by an experienced management team which has made three notable porphyry and bulk tonnage discoveries in North America and is sponsored by Altius Minerals (TSX: ALS), a large shareholder of the Company.About Gold Basin Resources CorporationGold Basin Resources Corporation holds the Gold Basin Project in Mohave County Arizona. The project hosts large, mineralized trends containing near surface oxide gold mineralization and has seen over 800 historic and current drill holes into mineralized deposits up to 1.7 kilometres in length."Shane Ebert"Shane Ebert, President/Director of CANEX and Gold BasinFor Further Information Contact:Shane Ebert at 1.250.964.2699 orJean Pierre Jutras at 1.403.233.2636Web: http://www.canexmetals.caNeither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Although information provided by Gold Basin for inclusion in this news release is believed by CANEX to be reliable, CANEX has not independently verified such information and cannot provide any assurance of its accuracy, currency, reliability or completeness. Although information provided by CANEX for inclusion in this news release is believed by Gold Basin to be reliable, Gold Basin has not independently verified such information and cannot provide any assurance of its accuracy, currency, reliability or completeness.Forward-Looking StatementsThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", "potential", "risk", "anticipated", "future", or "opportunity" or variations of such words and phrases or stating that certain actions, events or results "may", "can", "shall" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.In this news release, forward-looking statements relate to, among other things, statements regarding: the proposed acquisition by CANEX of all of the Gold Basin Shares pursuant to the Arrangement and the terms thereof; the benefits of the Arrangement; the receipt of necessary shareholder, court and regulatory approvals for the Arrangement; the anticipated timeline for completing the Arrangement; the Gold Basin Meeting and mailing of the management information circular regarding the same; the Term Loan; the terms and conditions pursuant to which the Arrangement will be completed, if at all; the anticipated benefits of the Arrangement; the anticipated filing of materials on SEDAR+; and continuation of CANEX and delisting of Gold Basin. These forward-looking statements are not guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the potential results discussed in the forward-looking statements.In respect of the forward-looking statements, CANEX and Gold Basin have relied on certain assumptions that they believe are reasonable at this time, including assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court, shareholder, stock exchange and other third party approvals and the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Arrangement. This timeline may change for a number of reasons, including unforeseen delays in preparing meeting materials; inability to secure necessary regulatory, court, shareholder, stock exchange or other third-party approvals in the time assumed or the need for additional time to satisfy the other conditions to the completion of the Arrangement. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times.Risks and uncertainties that may cause such differences include but are not limited to: the risk that the Arrangement or the Term Loan may not be completed on a timely basis, if at all; the conditions to the consummation of the Arrangement or the Term Loan may not be satisfied; the risk that the Arrangement or the Term Loan may involve unexpected costs, liabilities or delays; the possibility that legal proceedings may be instituted against CANEX, Gold Basin, and/or others relating to the Arrangement or the Term Loan and the outcome of such proceedings; the possible occurrence of an event, change or other circumstance that could result in termination of the Arrangement Agreement; risks relating to the failure to obtain necessary regulatory, court, shareholder, and stock exchange approvals; other risks inherent in the mining industry. Failure to obtain the requisite approvals, or the failure of the parties to otherwise satisfy the conditions to or complete the Arrangement or Term Loan, may result in the Arrangement or Term Loan not being completed on the proposed terms, or at all. In addition, if the Arrangement or Term Loan are not completed, the announcement of the Arrangement and the Term Loan and the dedication of substantial resources of CANEX and Gold Basin to complete the Arrangement and the Term Loan could have a material adverse impact on each of CANEX's and Gold Basin's share price, its current business relationships and on the current and future operations, financial condition, and prospects of each of CANEX and Gold Basin. CANEX and Gold Basin disclaim any responsibility to update these forward-looking statements, except as required by applicable laws.SOURCE: Gold Basin Resources Corporation Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - Anytime Fitness (the “Company”), a globally renowned 24-hour fitness chain, has seen strong growth across the Asia-Pacific region in recent years. Benefiting from a significant rise in public health awareness in the post-pandemic era, it has continued to accelerate its market expansion. In particular, Hong Kong, as a strategic growth market for the Company, is expected to reach the milestone of 50 clubs by the end of the year. A further 25 clubs have already secured funding, with potential to open an additional 30 to 40 clubs over the next few years. Meanwhile, the Company projects that its total number of clubs across the Asia-Pacific region will reach 2,500 to 3,000 over the next two to three years, underscoring its long-term commitment to and confidence in the regional market.A Truly Global Brand, Powered by Regional ExpertiseAnytime Fitness operates as a truly global brand, with a presence across 42 countries and territories on all seven continents, offering members seamless access to clubs worldwide. Unlike competitors that are merely international, Anytime Fitness delivers a globally connected fitness ecosystem, combining scale, consistency, and member-centric innovation.In Asia-Pacific, growth is led by Inspire Brands Asia (“IBA”), the master franchisee for Anytime Fitness across key markets including Hong Kong, Singapore, Thailand, the Philippines, Indonesia, Vietnam, Taiwan, and Malaysia. This structure enables strong regional execution while maintaining global brand standards.Community-Based Approach: Replicating Singapore’s Success in Hong KongThe core philosophy of Anytime Fitness is to bring fitness services into the community and provide a convenient, stress-free workout experience — a model that has proven successful worldwide. Ryan Cheal, Group Chief Operating Officer of IBA, said: “As a highly mature market in the region, we’ve sold around 200 franchises and operate more than 160 clubs in Singapore. Its market penetration and consumer patterns have provided a clear blueprint for our expansion in Hong Kong. With a similar market profile but a larger population base, Hong Kong offers substantial potential for community-based development. We are confident that we can replicate the success achieved in Singapore, and expect that once Hong Kong surpasses the critical milestone of 50 clubs, network effects will drive even faster growth.”Franchising Drives Scalable Expansion with End-to-End Support for PartnersIn terms of its operating model, Anytime Fitness operates a hybrid model of corporate-owned and franchised clubs. Currently, around 50% of clubs in Hong Kong are corporate-owned, enabling the brand to gain deep insights into the local market and provide more effective support to franchise partners. In contrast, the proportion of corporate-owned clubs in Singapore stands at around 20%. This structure ensures that the Company can maintain high service standards and brand consistency while expanding rapidly.The Company’s franchise ecosystem offers end-to-end support, including:- Site selection and club development; - Equipment and operational setup; - Marketing and member acquisition; - Training and business coaching for franchise partners. This integrated approach ensures consistency in member experience while enabling rapid and sustainable expansion. At present, around 80% of new clubs are opened by existing franchisees. Investors from sectors such as retail and F&B are also increasingly shifting their investments towards the health industry, demonstrating the model’s strong appeal and the market’s recognition of its growth potential.Tech-Powered Member Experience: Building a Comprehensive Health EcosystemIn response to the trend of intelligent transformation, Anytime Fitness is actively leveraging technology to enhance service value. To enhance member experience, Anytime Fitness continues to invest in technology and personalised wellness solutions. Its next-generation member app integrates:- Personalised training plans; - Class and trainer bookings;- Recovery guidance and nutrition support.The ecosystem is further supported by tools such as Evolt, a body composition analysis system capable of measuring over 40 biometric indicators, giving members deeper insight into their health and fitness progress. Currently, the app’s average daily member usage rate is around 30% to 35%, effectively strengthening user engagement and retention.Understanding the Hong Kong Member: Strength, Wellness, and LifestyleRecent member insights highlight evolving fitness priorities in Hong Kong:- 57% of members (3 in 5) prioritise strength training; - 16% (1 in 6) are driven by broader wellness goals, including mental health and overall lifestyle improvement. These trends reflect a structural shift in consumer behaviour, where fitness is no longer discretionary, but an essential part of modern living.Focusing on “Essential Health Needs” and “Human-Centered Connection”, with a Stable and Positive Industry OutlookDespite the complex macroeconomic environment, the Company remains optimistic about the outlook for the industry. Ryan noted that the fitness population is continuing to grow, with participation among seniors steadily increasing and health awareness rising. Consumer spending priorities are also undergoing a structural shift, with health and fitness having evolved from “discretionary spending” to “essential lifestyle”. Notably, younger demographics have shown a particularly strong willingness to invest in health, wellness, and longevity, providing the industry with resilience that transcends economic cycles.Looking ahead, Anytime Fitness will continue to innovate its products and services. It launched a new club design last month, enhancing the strength training and exercise recovery areas, and plans to further improve its nutrition guidance services next year. Ryan concluded, “In this technology-driven era, the Company will continue to uphold the core value of ‘human-centered connection’, using convenient, friendly, and professional services to help more people establish consistent exercise habits and embrace a healthier lifestyle. We are confident in the Asia-Pacific and Hong Kong markets and believe that future growth will be even faster and more innovative.”About Anytime FitnessAnytime Fitness is the largest and fastest-growing global fitness brands in the world, averaging 300 new clubs per year while serving over 5 million members at nearly 6,000 clubs in 42 countries and territories on all seven continents. Open 24-hours a day, 365 days a year, Anytime Fitness delivers personalized and affordable health and wellness training, coaching, nutrition, and recovery guidance for our members—in the club, in their homes, in their pockets, wherever they are and anytime they need it. All franchised clubs are individually owned and operated, and members have access to any Anytime Fitness club worldwide.For more information, please visit：https://www.anytimefitness.com/.Media Inquiries:Inspire Brand AsiaJerry Chow Email: Jerry.chow@inspirebrandsasia.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 中国抗体制药有限公司（"中国抗体"或"公司"，连同旗下附属公司统称"集团"，股份代号：03681.HK）欣然宣布，公司执行董事、主席兼首席执行官梁瑞安博士作为特邀嘉宾，出席了近日在英国伦敦举办的2026 LifeArc转化科学峰会（LifeArc Translational Science Summit）。作为转化医学领域具有全球影响力的盛会之一，本届峰会汇聚了来自世界各地的顶尖科学家、临床医师、行业领袖、政策制定者及投资机构。梁瑞安博士在峰会中发表了主旨报告，系统分享了中国抗体在自身免疫疾病领域的研发策略与核心管线的最新临床进展，并与国际同行展开深入交流。本届峰会由英国知名医学研究慈善机构LifeArc主办。LifeArc长期致力于推动早期科学研究向临床应用的转化，尤其在罕见病及未满足医疗需求领域具有深远影响力。峰会聚焦转化研究如何通过推进新型治疗手段、重塑临床实践、影响卫生政策及驱动商业创新，加速从实验室发现到惠及患者的全过程。与会嘉宾围绕抗体药物、基因治疗、细胞治疗等前沿领域展开跨学科对话，探讨如何破解转化医学中的关键瓶颈，促进产学研医协同发展。梁瑞安博士的受邀，标志着中国抗体在创新免疫治疗领域的探索已获得国际权威机构的高度关注。在峰会主题报告中，梁瑞安博士深入剖析了全球自身免疫疾病药物研发的格局与挑战，并重点阐述了中国抗体以"全球首创（First-in-Class）与同类最优（Best-in-Class）"为核心的差异化创新策略。他详细介绍了公司核心产品SM17——一款靶向白细胞介素25（IL-25）受体的人源化单克隆抗体。SM17通过精准作用于II型免疫反应上游的关键"警戒素"分子IL-25受体，从源头抑制炎症级联反应，具有治疗特应性皮炎（AD）、炎症性肠病（IBD）、哮喘、慢性鼻窦炎伴鼻息肉及特发性肺纤维化等多种炎症免疫性疾病的广阔潜力。梁博士分享了SM17在近期取得的一系列实质性进展：在AD领域，SM17的1b期临床研究显示出卓越的疗效，高剂量组91.7%的患者实现瘙痒缓解（NRS-4），75%达到皮损恢复（EASI 75），41.7%达到完全或近乎完全清除AD症状（IGA 0/1），疗效数据显著优于现有IL-4/IL-13类单抗，且安全性优于JAK抑制剂；基于此，SM17治疗中重度AD的II期临床试验已于2026年3月31日在中国完成首例患者给药，计划入组约210名患者，预计2026年下半年完成全部入组，2027年上半年获得顶线数据。在给药便利性方面，SM17皮下制剂的I期桥接研究于2026年3月25日取得积极顶线结果，30名健康受试者的数据显示皮下注射具有良好的安全性和药代动力学特征，仅有一例1级注射部位皮疹并自行消退，绝对生物利用度稳健，为后续开发更便捷的皮下给药方案奠定了基础。此外，SM17的适应症已成功拓展至IBD，其新药临床试验申请（IND）于2026年2月24日获中国国家药监局正式批准，涵盖克罗恩病及溃疡性结肠炎，相关桥接研究已于2026年2月完成，将直接推进至II期临床开发。梁博士还介绍了公司早期管线的创新布局：抗CGC抗体（全球首创人源化抗γc抗体）在治疗斑秃、白癜风等自身免疫性疾病中展现出潜力，计划于2026年第四季度提交IND申请；靶向RANKL及骨硬化蛋白的双特异性抗体在骨相关适应症的临床前研究中显示出优于现有上市药物的疗效，计划于2027年上半年提交IND申请。梁博士强调，中国抗体通过深耕创新靶点，逐步构建起具有协同效应的产品矩阵，旨在为全球患者提供更安全、更有效、更便捷的突破性治疗方案。此次受邀出席LifeArc转化科学峰会，不仅体现了国际权威机构对中国抗体创新研发实力与前沿探索的高度认可，也为公司深化全球合作提供了重要平台。通过与全球顶尖科学家、临床研究者及跨国药企高管的深入交流，中国抗体进一步拓展了国际学术网络与潜在合作渠道，为未来技术引进、联合研发、对外授权及商业化落地奠定了坚实基础。梁瑞安博士表示，公司将继续聚焦自身免疫性疾病领域未满足的临床需求，加速推进SM17等核心管线的全球多中心临床开发，同时积极探索运用人工智能等新技术赋能新靶点发现，并依托与中山大学香港高等研究院等机构的战略合作，强化从实验室到临床的转化能力。展望未来，中国抗体将把握中国生物医药对外授权高速增长的历史机遇，坚持差异化的全球创新路径，积极寻求与全球伙伴的多元化合作模式，推动创新成果更快惠及全球患者，为股东创造长期价值。关于中国抗体制药有限公司中国抗体制药有限公司（股份代号：03681.HK）是首创新药及潜在同类最佳抗体药物研发领域的开拓者，专注于自身免疫性疾病、以及由此导致的神经系统疾病及其他难治的耗损性疾病，致力于解决未被满足的医疗需求。中国抗体始终致力于开发针对全新靶点及通过创新机制的治疗性抗体，旨在现有疗法效果不佳的领域实现差异化临床成果。其丰富的研发管线包括：SM17在AD治疗中展现出卓越的止痒效果、皮肤清除率及安全性，同时在哮喘和特发性肺纤维化（IPF）领域具有应用潜力；其旗舰抗CD22舒西利单抗，除了临床验证对类风湿关节炎（RA）具有临床疗效外，目前正针对系统性红斑狼疮（SLE）和阿尔茨海默病开展临床评估；另一款抗CGC（共同γ链）创新单抗，正准备进入治疗斑秃和白癜风的临床研究；中国抗体亦研发了一款能同时刺激骨骼生长及抑制骨骼流失、治疗骨质疏松症的双特异性抗体。中国抗体以突破性疗效为核心追求，不断重新定义患者护理标准，稳居突破性疗法领域的领军地位。此新闻稿由真灼财经代中国抗体制药有限公司发布投资者及媒体查询联络人：Bunny LeeNomia ZhouQiuyan Deng电话：（852）5316 9995电邮：ir_sinomab@zhenzhuoglobal.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab’s R&D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year’s summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung’s invitation to this high-profile event marks high recognition from leading international authorities of SinoMab’s innovative efforts in immunotherapy.In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&D for autoimmune disease therapeutics, and elaborated on SinoMab’s differentiated innovation framework anchored in “First-in-Class” and “Best-in-Class” drug development. He gave a detailed introduction to SM17, the Company’s flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn’s disease and ulcerative colitis was officially approved by China’s National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company’s innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab’s innovative edge and exploratory work in antibody R&D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China’s biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeNomia ZhouQiuyan DengPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Anson Resources and POSCO Holdings have received board approval for a binding agreement to develop POSCO's Direct Lithium Extraction ("DLE") Demonstration Plant at the Green River Lithium Project in Utah.POSCO to lead the project at its own expense including the design, construction and operation of its proprietary Direct Lithium Extraction ("DLE") Demonstration PlantPOSCO to pay ~AUD $7.2 million (USD $5.2 million) non-dilutive facilitation fee to Anson.The collaboration positions Green River as a potential cornerstone asset in the emerging U.S. critical minerals and battery supply chain.During operation of the demonstration plant, the parties will evaluate broader commercial opportunities, including potential future joint investment and strategic cooperation.NEWPORT BEACH, CA, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson" or the "Company") is pleased to announce that both POSCO Holdings Inc. ("POSCO")'s board and the Company's board have approved the terms for a definitive Demonstration Plant Agreement ("Agreement") relating to the construction and operation of a Direct Lithium Extraction ("DLE") demonstration facility at the Green River Lithium Project in the Paradox Basin, Utah, USA.The board approvals mark a significant progression from the previously announced Memorandum of Understanding (see ASX Announcement 30 June 2025), establishing a framework under which POSCO will operate its own non-commercial DLE demonstration plant designed to validate lithium extraction at continuous industrial scale.Under the agreement POSCO committed to setting up its DLE demo-plant to extract lithium from brines produced from the Bosydaba #1 well owned by Anson at the Green River Lithium Project. POSCO will be responsible for engineering, construction, operation and maintenance of the facility, while Anson will provide access to property, infrastructure and brine supply. POSCO will pay Anson a non-dilutive facilitation fee of AUD ~$7.2 million (USD $5.2 million).The definitive agreement is expected to be signed before the end of Q2 2026. POSCO is expected to commence operation of the demonstration plant in 2027 and complete the work in 2028.The two companies will continue to explore potential business cooperation opportunities, including joint investment in the Project, during the operation of the demonstration plant, as outlined in the MoU Agreement, see ASX Announcement 30 June 2025.Strategic ImportanceDemonstrates strong industry validation of Green River's low-cost lithium potential.Accelerates technical de-risking through continuous demonstration-scale testing.Positions Green River as a key participant in the emerging U.S. domestic battery materials supply chain.Executive CommentaryExecutive Chairman & CEO, Mr. Bruce Richardson commented:"Securing a definitive agreement with POSCO represents a transformational step forward for the Green River Lithium Project.Moving from a non-binding MoU to a fully executed agreement underscores the strong technical confidence POSCO has in our asset and highlights the increasing strategic importance of domestic U.S. lithium supply."POSCO Holdings commented:"With the approval of the terms for a binding agreement, POSCO Holdings will advance validation of DLE technology in the United States and evaluate commercialisation pathways for future lithium production.We believe collaboration with Anson Resources at Green River will contribute to strengthening the North American lithium supply chain."Key Elements of the Definitive AgreementItemKey TermsProjectNon-commercial DLE Demonstration Plant - Green River Lithium ProjectResponsibilityPOSCO to bear cost for the design, construction, operations and maintenance for Demonstration PlantFacilitation FeeUSD $5.2MTermTo December 2028Brine SupplyProvided from Bosydaba #1 well with defined performance targetsAbout POSCO HoldingsPOSCO Holdings Inc. is a leading South Korean industrial group with strategic investments across steel, energy, and battery materials. POSCO Group is developing a global supply chain to support the transition EV and has invested in a total of 93,000 tonnes of lithium production annually in Argentina and South Korea. The company has made significant investments in both brine and hard-rock lithium resources across South America and Australia and is advancing proprietary Direct Lithium Extraction (DLE) technologies to accelerate low-carbon lithium production.This announcement has been authorized for release by the Executive Chairman and POSCO Holdings.For further information please contact:Bruce Richardson Will MazeExecutive Chairman and CEO Head of Investor RelationsE: info@Ansonresources.com E: investors@Ansonresources.comPh: +61 7 3132 7990 Ph: +61 7 3132 7990www.Ansonresources.com Follow us on Twitter @Anson_irSOURCE: Anson Resources Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com